Harmony Biosciences (HRMY) Stock Price & Analysis

HRMY$33.76-0.04 -0.12%
BiotechnologyValue StockGrowth StockHigh Quality
Compare
Market cap$1.98BEnterprise value$1.38BRevenue (TTM)$989.36MMarket position—

Score

74
Bullish
Value
70
Quality
77
Growth
76

AI Analysis

Snapshot

Harmony Biosciences Holdings mixes growth with a still-reasonable multiple — Growth 76/100 with P/E 11.2, about 25% below its own multi-year median. Under the hood: P/E 11.2, about 25% below its own multi-year median, plus revenue compounding ~26% annually over recent years. Street targets still imply ~44% upside.

Price History

Bullish (65+)Neutral (45–64)Bearish (<45)

Score Breakdown

Market percentile scores loading…

Value

70
PE Ratio (F)–
PEG Ratio–
Free Cashflow Yield %–
EV/EBITDA Ratio–
Discount vs All Time Peak–
Discount vs 1Y Peak–

Growth

76
Earnings Forecast–
Last 3M Earnings Growth %–
12M Revenue Growth %–
12M Earnings Growth %–
5 YR CAGR % Earnings–
Analyst Price Forecast–

Quality

77
FCF Margin %–
Net Debt / EBITDA–
Operating Margin %–
Operating Margin Growth %–
ROCE %–
Current Ratio–

Financial Summary

Harmony Biosciences Holdings, Inc. (HRMY) last printed $33.76. Equity value is $1.98B. Trailing earnings multiple 11.04. The revenue row is reported history. Targets and ratings are on the forecast page.

Financials

20182019202020212022202320242025
$0.00$6M$159.74M$305.44M$437.86M$582.02M$714.73M$868.45M

About

Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical firm dedicated to developing and marketing therapies for individuals in the United States who suffer from rare neurological conditions. Their flagship product, WAKIX, is a prescription medication designed to treat excessive daytime sleepiness in adult patients diagnosed with narcolepsy. The company, which was founded in 2017, was formerly known as Harmony Biosciences II, Inc. before adopting its current name in February 2020. Harmony Biosciences Holdings, Inc. operates out of Plymouth Meeting, Pennsylvania.

Harmony Biosciences (HRMY) Stock Price & Analysis

HRMY price $33.76 -0.04 -0.12%

Ticker
HRMY
Price
$33.76
Change
-0.04 -0.12%
Market cap
$1.98B
P/E
11.04
Forward P/E
9.71
Dividend yield
0.00%
Beta
0.98
Sector
Healthcare
Industry
Biotechnology
Stocklytics score
74
Value
70
Quality
77
Growth
76

Stocklytics score rationale: value 70, quality 77, growth 76.

Insights · Forecast · Financials · Learn

Stocklytics home · Screener